Monocytes contribute to arteriogenesis by infiltration to sites of collateral growth and subsequent production and release of growth factors. Transforming growth factor b1 (TGF-b1) mediates monocyte motility and stimulates arteriogenesis. TGF-b1 signalling mechanisms mediating monocyte motility are unknown so far. Moreover, the influence of cardiovascular risk factor diabetes on TGF-b1-induced monocyte migration remains to be elucidated.
Introduction
Stable chronic and repetitive myocardial ischaemia triggers coronary collateral growth based on the process of arteriogenesis, 1 resulting in partly compensated regional myocardial perfusion. Arteriogenesis inclines flow in the neighbouring pre-existing collateral network, in turn elevating fluid shear stress at the sites of the collaterals. Consequently, growth factors, cytokines, and receptors are up-regulated by shear-stress-damaged endothelium and underlying smooth muscle cells, increasing the recruitment and diapedesis of monocytes. 2 -4 Monocytes are indispensable mediators aiding in the structural growth and outward remodelling of collaterals. 5, 6 Transforming growth factor b1 (TGF-b1) is crucially involved in arteriogenesis, is present in areas of ischaemia and collateral growth, 7 -9 and is up-regulated in vascular endothelial cells by fluid shear stress. 10 This 25 kDa dimeric pro-arteriogenic protein is a well-established nonchemokine chemoattractant known to exert a substantial chemotactic effect on an entire array of cell types, 11 -13 including monocytes. 14 -16 Hence, TGF-b1 is likely to be, alike monocyte chemoattractant protein 1 (MCP-1) and members of the vascular endothelial growth factor (VEGF) family, 17 -19 responsible for monocyte attraction to sites of collateral growth. In line, intra-arterial delivery of TGF-b1 to neighbouring collateral sites of occluded lesions showed higher rates of perfusion, correlating with increased macrophage content. 20 TGF-b1 signals via assembly of a heterotetrameric TGF-b receptor complex composed of type 1 and 2 dual specificity kinase receptors. Upon ligand binding to the constitutively active type 2 TGF-b receptor (TbR2), the type 1 receptor (TbR1), also known as activin receptor-like kinase 5 (ALK5), is recruited into the complex and phosphorylated by TbR2. In turn, ALK5 activates downstream SMA/MAD homologues proteins (SMAD). Receptor-regulated SMAD2 and SMAD3 are phosphorylated and form a heteromeric transcription factor complex with the common SMAD4, which translocates to the nucleus and regulates transcription of target genes. 21 Besides the SMAD pathway, incitement of the TGF-b receptors have been shown to activate non-SMAD signalling pathways. These include the phosphoinositide 3 kinase (PI3K), v-Akt murine thymoma viral oncogene analogues protein (AKT), extracellular signal-related kinase (ERK) 1/2 and p38 cascades, which have been postulated to be principal effectors of TGF-b1-mediated cellular responses such as migration. 22 -25 In addition, concerted cross-talk and direct interactions between SMADs and AKT, ERK1/2, and p38 establish or tune specific cellular actions. 26 -31 While the actions of TGF-b1 on monocyte migration have been previously described, the molecular mechanisms by which TGF-b1 induces monocyte chemotaxis are largely unknown. In this study, we addressed the involvement of ALK5 and both SMAD and non-SMAD pathways in the TGF-b1-driven chemotactic response of monocytes. Diabetes mellitus (DM) retards arteriogenesis due to detrimental effects on the recruitment of relevant circulating cells to the vessel wall mediated by arteriogenic factors. 18, 32, 33 Along this line, our previous studies have shown both functional and mechanistic signalling impairments of diabetic monocytes in response to other arteriogenic cytokines. 18, 19, 34, 35 Nevertheless, the impact of cardiovascular risk factors such as DM on TGF-b1-induced monocyte migration has not been studied previously. Therefore, we determined the functional ability of TGF-b1 in stimulating monocytes derived from patients with type 2 DM.
In the current study, we characterized the downstream molecular mechanisms through which TGF-b1 regulates motility of primary human monocytes and the effect of the cardiovascular risk factor DM hereon. Our results suggest that TGF-b1 induces both SMAD and non-SMAD pathways in an ALK5-dependent manner. While inhibition of ALK5 activity resulted in abolished TGF-b1-induced monocyte chemotaxis and prevented activation of SMAD and non-SMAD signalling, specific knock-down for SMAD2 or SMAD3 did not affect TGF-b1-driven monocyte migration. Furthermore, our results reveal a crucial role for PI3K and p38 in TGF-b1-induced monocyte chemotaxis. In addition, we demonstrate that DM does not negatively affect monocyte migration towards TGF-b1.
Methods

Cells and reagents
Experiments were performed with human peripheral blood monocytes, isolated from commercially available buffy coats obtained from the Centre de Transfusion Sanguine (Liege, Belgium) or from peripheral blood of patients. Recombinant human TGF-b1 was obtained from Peprotech Inc., (Rocky Hill, CT, USA). PI3K inhibitor Wortmannin, p38 inhibitor SB239063, and ERK1/2 kinase inhibitor PD98059 were purchased from Sigma-Aldrich (Saint Louis, MO, USA). ALK5 inhibitor LY364947 was obtained from Tocris Bioscience (Ellisville, MO, USA). The AKT-VIII inhibitor and cycloheximide were purchased at Merck KGaA (Darmstadt, Germany). Antibodies recognizing phosphorylated forms of SMAD2 (Ser456/467), AKT (Ser473), ERK1/2 (Thr202/Tyr204), and p38 (Thr180/Tyr182) and total SMAD2, SMAD3, AKT, and ERK1/2 were purchased from Cell Signaling Technology Inc., (Danvers, MA, USA). The p38 antibody was obtained from BD Biosciences (San Jose, CA, USA). b-Actin antibody was ordered from Sigma-Aldrich. PRAK and phosphorylated PRAK (Ser93) and secondary horseradish peroxidase-conjugated antibodies were from Santa Cruz Biotechnology Inc., (Santa Cruz, CA, USA).
Isolation of monocytes
Monocytes were isolated by means of density gradient centrifugation followed by a magnetic-bead-based immunological isolation assay. In brief, density centrifugation was performed using Histopaque (1.077 g/mL) separation (Sigma-Aldrich Inc.) to isolate peripheral blood mononuclear cells. Subsequently, monocytes were extracted from the mononuclear fraction using the MACS monocyte isolation kit II (Miltenyi Biotec GmbH, Bergische Gladbach, Germany), according to the manufacturer's protocol. The freshly enriched monocytes had a viability of .95%, according to Trypan-blue assessment. 
Western immunoblotting
Monocyte chemotaxis
Chemotaxis assays were performed using Boyden chamber methodology as previously described, 19 with modifications for this study as described in Supplementary material online.
RNAi for SMAD2 and SMAD3
SMAD2 (Dharmacon Inc., Lafayette, CO, USA) and SMAD3 (Santa Cruz Biotechnology Inc.) siRNAs were provided as pools of target-specific sequences.
SMAD2 siRNA:
RNAi experiments were performed using the Amaxa human monocyte nucleofector kit (Lonza, Verviers, Belgium), according to the manufacturers' protocol, using 5 × 10 6 monocytes and 160 pmol of siRNA per assay (total volume 1.6 mL, final concentration 100 nM siRNA). After transfection, cells were cultured for 20 h. Subsequently, transfected monocytes were analysed for their functional migratory response to TGF-b1. Silencing efficiency was determined by western blotting for TGF-b1/ALK5-induced monocyte migration SMAD2 and SMAD3. Monocyte viability after transfection was .90%, according to Trypan-blue assessment.
Characterization of patient groups
Patients suffering from type 2 DM and non-DM control subjects were characterized ( Table 1 ) and studied. This study was conformed to the principles outlined in the Declaration of Helsinki. The study protocol was approved by the Ethical Committees of the University Hospital of Maastricht (The Netherlands). Informed consent was obtained from participants according to the requirements of the local ethical committee.
Statistical analysis
Results are expressed as mean + SEM. Migration is presented as percentages over chemokinesis of unstimulated (vehicle/mock) controls, set at 100%. Immunoblotting data are provided as fold over unstimulated (vehicle/mock) control values, set at 1 fold. Statistical analysis was performed by two-tailed Student's t-test, using (i) paired samples analysis for + TGF-b1 intra-condition comparison (n ¼ 4), (ii) homoscedastic two-sample equal variance analysis for + inhibitor inter-condition comparison (n ¼ 4), and (iii) two-sample non-equal variance analysis for DM vs. non-DM separate condition comparison (n ¼ 11). A probability (P) value of ,0.05 was considered significant.
Results
TGF-b1 activates SMAD2, AKT, p38, and ERK1/2 in primary human monocytes via ALK5
In this study, we aimed to characterize the signalling pathways required for TGF-b1-mediated monocyte chemotaxis. Stimulation of primary human monocytes was performed in a kinetic manner, correlating with the length of time (90 min) of the chemotaxis assay, adopting 10, 30, 60, and 90 min as observatory time points. TGF-b1 stimulation resulted in maximum induction of SMAD2 phosphorylation already after 10 min ( Figure 1A) . TGF-b1 also induced phosphorylation of downstream non-SMAD signalling molecules AKT, ERK1/2 and p38 ( Figure 1A) . Phosphorylated AKT and p38 reached plateau levels at 60 min. TGF-b1-activated ERK1/2 inclined up to the 90 min endpoint, with the largest increment from 30 to 60 min ( Figure 1A ). For consecutive protein activity experiments, monocytes were incubated for 60 min with TGF-b1. Next, we scrutinized the functional role of ALK5 in TGF-b1-induced monocyte migration. Blockade of the ATP-binding site of ALK5 with 1 mM of the pharmacological ALK5-kinase inhibitor LY364947 abrogated TGF-b1 chemotaxis, clearly indicating that the type 1 receptor is required for monocyte movement towards TGF-b1 ( Figure 1B) . Interestingly, treatment with LY364947 prevented not only TGF-b1-triggered SMAD2 phosphorylation but also TGF-b1-induced AKT, ERK1/2, and p38 activation ( Figure 1C ). These results demonstrate that ALK5 kinase activity is required for both the activation of SMAD and non-SMAD cascades and monocyte chemotaxis.
SMAD2 and SMAD3 are not implicated in monocyte migration
To investigate whether TGF-b1 promotes monocyte migration by transcriptional activation of target genes, we assessed the effect of the general transcriptional inhibitor cycloheximide. Pre-treatment of monocytes with 50 mM cycloheximide did not affect monocyte chemokinesis or TGF-b1-induced chemotaxis (Figure 2A ). This data corroborate that monocyte migration towards TGF-b1 does not require transcription of target genes and de novo protein synthesis, but is rather mediated by direct protein signalling. SMAD proteins predominantly serve as transcriptional promoters; however, they can also modulate TGF-b1 signalling by interaction or cross-talk with other signalling molecules. In order to specifically address the involvement of the SMAD pathway in monocyte migration, the SMAD2 and SMAD3 genes were individually silenced via siRNA technology. We were able to reduce the cellular SMAD2 and SMAD3 content by, respectively, 83 and 71% with target-specific siRNAs ( Figure 2B ). Scrambled control siRNA did not alter SMAD2 and SMAD3 levels ( Figure 2B) . The obtained SMAD knock-downs did not affect TGF-b1-induced migration in comparison with the chemotactic responses of mock and scrambled controlled transfected monocytes, nor monocyte chemokinesis ( Figure 2C ).
3.3 TGF-b1-directed monocyte migration requires PI3K, but not its downstream substrate AKT Selective pharmacological inhibition was applied to determine the functional roles of PI3K and AKT signalling in monocyte chemotaxis towards TGF-b1. Inhibition of the p110 subunit of PI3K with 25 nM Wortmannin not only abrogated chemotaxis towards TGF-b1, but, moreover, diminished basal motility of monocytes ( Figure 3A) . Wortmannin prevented AKT phosphorylation by TGF-b1. However, Wortmannin had no effect on TGF-b1-induced SMAD2, ERK1/2 and p38 phosphorylation ( Figure 3B) . Remarkably, PI3K impairment augmented basal levels of activated p38 by 2.44-fold ( Figure 3B ). This distinct PI3K control over p38 activity was confirmed by the use of another PI3K inhibitor LY294002 at 5 mM (data in Supplementary material online, Figure S1 ). In addition, we defined the role of the PI3K downstream substrate AKT in TGF-b1-induced monocyte chemotaxis. By design, the AKT-VIII inhibitor prevented AKT phosphorylation, yet the activation of SMAD2, p38 and ERK1/2 by TGF-b1 was not modified ( Figure 3D ). AKT inhibition did not affect monocyte chemotaxis to TGF-b1 ( Figure 3C ). Our results conclude that PI3K, but not AKT, is pivotal in regulating chemotaxis towards TGF-b1 and propagates the basal motility of monocytes.
Roles of ERK1/2 and p38 in TGF-b1-induced monocyte motility
We assessed the requirement for ERK1/2 and p38 in TGF-b1-driven chemotaxis of human monocytes. Treatment of monocytes with the ERK1/2 kinase (MEK) inhibitor PD98059 at 25 mM left basal and ligand induced monocyte motility unaltered ( Figure 4A ). PD98059 not only inhibited TGF-b1-induced ERK1/2 phosphorylation, but also the activation of AKT by TGF-b1, whereas the phosphorylation of SMAD2 and p38 remained intact ( Figure 4B ). In contrast, pre-incubation with the p38 inhibitor SB239063 abolished TGF-b1-mediated monocyte chemotaxis ( Figure 4C ). SB239063 functionally inhibited p38, as demonstrated by prevention of TGF-b1-induced activation of PRAK, a p38 substrate ( Figure 4D ). After SB239063 treatment, TGF-b1 could still induce phosphorylation of SMAD2, AKT and ERK1/2 ( Figure 4D ). In summary, p38 rather than the MEK/ERK pathway actuates TGF-b1-directed monocyte migration.
DM does not impair TGF-b1-mediated monocyte chemotaxis
Since our previous studies suggested that DM evokes defective monocyte migration to certain cytokines, we questioned whether DM would affect TGF-b1-driven chemotaxis. Monocytes from 11 type-2 DM diagnosed patients and 11 non-DM control subjects ( Table 1) were isolated and functionally evaluated for their migratory responses towards TGF-b1. We also analysed the effect of PlGF-1 on DM monocyte migration. Our results verify that DM monocytes are deprived of their ability to migrate towards PlGF-1 ( Figure 5) . Surprisingly, the migratory response of DM TGF-b1/ALK5-induced monocyte migration monocytes towards TGF-b1 was comparable with that of non-DM control monocytes ( Figure 5 ).
Discussion
Cardiac repair by arteriogenesis relies on proper growth factor signalling and monocyte infiltration, both promoting appropriate collateral conductance and regional perfusion. The arteriogenic growth factor TGF-b1 is a mediator of monocyte motility; however, it is not known through which mechanisms this is achieved. In the present study, we investigated SMAD and alternative non-SMAD signalling pathways of TGF-b1 in monocytes, in order to identify the molecular mechanisms manifesting TGF-b1-induced motogenicity. We also focused our attention on the influence of diabetes on the migratory response of monocytes to TGF-b1.
On the basis of our data, we propose a signalling model for TGF-b1 activation of monocytes and the regulation of cellular motility herein ( Figure 6 ). Treatment of monocytes with TGF-b1 resulted in phosphorylation of AKT, p38, ERK1/2, and SMAD2. We specifically addressed the requirement of ALK5 in the activation of these downstream signalling components and monocyte migration. It has been reported previously that binding and activation of several intracellular proteins, for instance TRIP1, 36 can occur solely via the constitutive type 2 receptor TbR2. Also DAXX, involved in MAPK pathway activation by TGF-b1, was identified to be interacting with the cytoplasmic tail of TbR2. 37 Likewise, polarity protein PAR6, which regulates cellular plasticity, is a direct substrate of TbR2. 38 It has even been described that TGF-b1-induced chemotaxis of MCF-7 and MDA-MB-468 cells can still be progressed after inhibition of ALK5 kinase activity. 39 Whereas these data theorize an ALK5-independent manner of TGF-b1 signalling, we on the other hand have been able to demonstrate that ALK5 receptor activity is essential for the induction of monocyte migration. The ostensible cause for this effect lies in the abrogation of signalling to downstream chemotaxis-related messengers p38 and PI3K. Activation of SMAD2 and ERK1/2 was also impaired after ALK5 inhibition, evincing the utmost requirement of the inducible type 1 receptor for integral TGF-b1 signalling in monocytes.
TGF-b1 signals canonically to SMAD2 and SMAD3, which function as TGF-b1-induced transcriptional regulators. In order to investigate whether migration of monocytes towards TGF-b1 is mediated via gene expression, we inhibited transcription with cycloheximide. Our results using cycloheximide affirm that the effect of TGF-b1 on TGF-b1/ALK5-induced monocyte migration monocyte attraction is not transcription-dependent. Although (SMADmediated) transcription is not crucial in propagating monocyte chemotaxis, SMADs have been demonstrated to regulate cellular household and function via transcription-independent cross-talk with non-SMAD elements AKT, ERK1/2, and p38. 27, 28, 30, 31 Recently, a direct AKT and SMAD3 interaction was discovered in which endogenous AKT associates with SMAD3, co-ordinating apoptosis. 29 Previous studies have shown that SMAD2 and SMAD3 are involved in cancer cell migration in vitro, since knockdown of SMAD2 or SMAD3 inhibited TGF-b1-induced migration of breast cancer cell line MDA-MB-123. 40 To date, no investigations have been conducted to elucidate whether these SMADs take part in the transduction of the chemotactic response of monocytes. We hypothesized that the loss of SMADs or the loss of SMAD cross-talk and interaction possibilities with motility driving kinases might affect the motogenicity of monocytes. Through individual transient knock-down of SMAD2 and SMAD3 genes, we were able to significantly decrease corresponding protein levels to, respectively, 17 and 29% of the original cellular content. Nonetheless, monocyte chemotaxis towards TGF-b1 remained in tact. Similar degrees of SMAD2 and SMAD3 reductions were sufficient to fully impair protein expressions and particular cellular functions. 41 -43 Taken together, we concluded TGF-b1-induced and random monocyte migration to be unassociated with both SMADs. PI3K, AKT, ERK1/2 and p38 kinases represent alternative non-SMAD mechanisms activated by TGF-b1, which have been earlier implicated in TGF-b1-induced motility of other cell types. A549 cells utilize PI3K and AKT to increase cellular motility as a consequence of activated integrins. 24 PI3K also regulates migration of NMuMG cells upon TGF-b1 stimulation. 44 The ERK1/2 pathway, rather than p38, is the predominant effector of mast cell migration. 25 In MDA-MB-231 cells, both increased AKT as well as ERK1/2 phosphorylation are associated with motility. 23 On the other hand, fibroblastic cells require p38 for TGF-b1-mediated migration. 22 Through pharmacological intervention experiments, we were able to demonstrate that migration of primary human Figure 5 DM does not affect monocyte chemotaxis to TGF-b1.
Monocytes were isolated from 11 type-2 DM and 11 non-DM study subjects. Isolations and concurrent chemotaxis experiments occurred independently from one another. Monocytes were analysed for their migratory responses towards 5 ng/mL TGF-b1 and 1 ng/mL PlGF-1. Figure 6 Model for TGF-b1 signalling in primary human monocytes. Stimulation of monocytes with TGF-b1, channelled through TGF-b type 1 receptor ALK5, leads to the activation of the PI3K, AKT, MEK/ERK, p38/PRAK and SMAD mechanisms. The canonical SMAD pathway does not play a crucial role in monocyte motogenicity to TGF-b1. Basal monocyte motility and TGF-b1-mediated chemotaxis are strongly dependent on PI3K. However, AKT is not required for migration to TGF-b1. Furthermore, PI3K controls basal phosphorylated p38 levels. The MEK/ERK mechanism is not involved in TGF-b1-induced monocyte motility. TGF-b1-triggered AKT phosphorylation relies on MEK/ERK. Finally, monocyte chemotaxis is also dependent on p38. Plausibly, this p38 motility cascade progresses through TGF-b1-activated p38 substrate PRAK, as PRAK is known to regulate actin dynamics, governing cell migration.
monocyte towards TGF-b1 depends on PI3K, but does not require AKT activity. The ERK1/2 pathway, although activated by TGF-b1, is not crucially involved in the motogenicity of monocytes. Per contra, blockade of p38 kinase function prevented monocyte chemotaxis. We validated proper p38 inhibition by SB239063 through the activation of direct p38 downstream target PRAK, as SB239063 blocks p38 kinase function, not p38 phosphorylation. Activation of PRAK was indeed impaired after treatment with SB239063. This p38 substrate regulates actin filament dynamics leading to cellular migration. 45, 46 Hence, it is plausible that monocytes adopt this PRAK cascade downstream of the activated p38 for its contribution in the chemotactic process towards TGF-b1. Cross-examination under the individual pharmacological inhibitory conditions revealed that activation of SMAD2, AKT, p38 and ERK1/ 2 by TGF-b1 are not dependent on one another, except in the case of ERK1/2 kinase inhibition by PD98059, which lead to the impairment of TGF-b1-induced AKT phosphorylation. Evidently, the MEK/ERK dyad is essential in monocytes for the augmentation of AKT by TGF-b1. Furthermore, we observed several prominent effects unrelated to TGF-b1. Due to the marked effect of Wortmannin in our functional model, it appears that PI3K is tremendously crucial not only for directed chemotaxis, but random/basal monocyte motility as well. We also discovered a remarkable interplay between the PI3K and p38 mechanisms in monocytes. Surprisingly, inhibition of PI3K with Wortmannin had a significant positive effect on basal levels of active p38, which was verified to be genuine by the use a second PI3K inhibitor LY294002. Cleary, PI3K governs p38 activity in monocytes, emphasizing its intrinsic regulative authority.
Finally, we determined the effect of DM on the mobilization of monocytes by TGF-b1. Previous reports showed marked migratory defects of diabetic monocytes. In particular, monocytes showed resistance towards chemokines and growth factors such as MCP-1, 18, 32 macrophage inhibitory protein-1, 32 SHH 34 and members of the VEGF family 18, 19, 35 in both human and experimental animal models. Remarkably, DM did not influence the chemotactic action of TGF-b1 on primary human monocytes, whereas PlGF-1-stimulated diabetic monocytes showed a migratory impairment in line with prior findings. 35 Comparing our TGF-b1 migration model with VEGF receptor-induced downstream signalling in monocytes, 47 there is a clear distinction between the cascading of PI3K, ERK1/2, and p38 signals and their individual involvement in monocyte motility. The impaired migratory response of monocytes to VEGF-A and PlGF-1 is attributable to pathophysiological cellular household, e.g. reductions in phosphatase activities, as a result from diabetes-related inclination of advanced glycation end products and oxidative stress. 35 Differences in susceptibility and cross-talk to these pathophysiological mechanisms might be causal for the discrepancy between the responses of TGF-b1 and VEGF family members. In addition, the contrasting chemotactic response of diabetic monocytes to TGF-b1 vs. other cytokines is also likely to evolve from the acquirement of differential signalling components and diverging downstream pathways, cytokine-specific membrane receptor function, and the duration and intensity of the cytokine-induced signal. The pro-arteriogenic effects of TGF-b1 on the inclination of macrophage content and corresponding restoration of perfusion have been previously validated. 20 Together with our current discovery regarding the distinct positive migratory response of diabetic monocytes, TGF-b1 appears to be a superior and promising candidate for the therapeutic stimulation of arteriogenesis in patients suffering from DM and occlusive vascular diseases. In summary, these data present the molecular basis for monocyte migration to TGF-b1. TGF-b1-mediated monocyte chemotaxis and underlying molecular signalling are activated through ALK5. Monocyte migration towards TGF-b1 relies on the combined mechanisms of PI3K and p38, while being independent from AKT, MEK/ERK and SMAD2/3. In addition, TGF-b1-induced monocyte chemotaxis is resistant to the negative effects of DM.
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